ACAnil Chimakurthy

Anil Chimakurthy

*This is an algorithmically generated author record based on publicly available information.

Anil Chimakurthy has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perampanel, Lacosamide, Eslicarbazepine Acetate, and Brivaracetam in Adults Aged ≥65 Years with Epilepsy: A Narrative Review of Real‐World Evidence and Practical Prescribing Considerations

    by Margaret Gopaul, Anil Chimakurthy, Viswabhaskar Susarla, Andres Kanner

    Epilepsy prevalence sharply increases after age 65 years, but elderly adults are chronically underrepresented in key trials that form the licensing evidence base for antiseizure medications (ASMs), leaving clinicians to extrapolate from the experiences of younger cohorts. This narrative review aims to consolidate real-world evidence regarding the efficacy, safety, and tolerability of 4 commonly prescribed newer ASMs, perampanel (PER), lacosamide (LCM), eslicarbazepine acetate (ESL), and brivaracetam (BRV) among adults ≥65 years, provide pragmatic prescribing recommendations based on this evidence, and define key gaps where further study should be prioritized. Collating data from our structured search of observational cohorts, interventional trials and extensions, pooled and post hoc analyses, pharmacovigilance databases, and case series and reports, we found that reported effectiveness outcomes in older adults were generally comparable to those observed in broader adult populations, although heterogeneity across studies limits direct comparisons. ESL monotherapy produced 1-year retention rates of 72.7% and 6- and 12-month seizure freedom rates of 72.2% and 67.3% among patients ≥65 years; adjunctive LCM demonstrated superior seizure freedom rates among older versus younger patients (56.7% vs. 43.1%); and dedicated ≥65-year-old studies of ESL and BRV reaffirmed efficacy observed in overall populations, frequently at lower doses and slower titration schedules. Key safety signals were drug-specific: hyponatremia (more common and symptomatic in older adults) for ESL; dose-dependent PR interval prolongation and rare high-grade atrioventricular block/ventricular tachycardia, Brugada morphology, and sinus node dysfunction for LCM; and psychiatric or behavioral events, dose-dependent falls for PER. Evidence supported a class-wide relationship between chronic ASM exposure and falls and fractures, while a FAERS analysis found no significant drug reaction with eosinophilia and systemic symptoms (DRESS) signal for BRV and analysis-dependent findings for LCM. In conclusion, newer ASMs are efficacious and generally well tolerated among older adults. However, optimized safe prescribing in this population requires ASM selection tailored to comorbidities, lower starting doses with slower titration, and drug-specific follow-up (e.g., serum sodium monitoring for ESL, cardiac conduction assessment for LCM, and behavior and fall risk assessment for PER). Evidence remains lacking in adults ≥65 years of age, particularly for brivaracetam.

  • Open Access

    Seizure prophylaxis versus epilepsy prevention after acquired brain injury: a cross-sectional clinicaltrials.gov registry analysis, 2000–2026

    by Anil Chimakurthy, Viswabhaskar Susarla, Jeet Hemantkumar Chaudhary, Om Desai

    Seizures after acquired brain injury pose distinct therapeutic questions: early seizure prophylaxis, treatment of acute symptomatic seizures, and late epil

  • Open Access

    Defining the end point of status epilepticus: A scoping review and framework for standardization

    by Fawad A. Khan, Margaret T. Gopaul, Samuel L. Carter, Anil Chimakurthy, Summer Skelton, Lawrence J. Hirsch, Eugen Trinka

    Status epilepticus (SE) is a life‐threatening neurological emergency with consensus‐driven definitions for onset but no standardized criteria for its end point. This gap creates uncertainty in research and clinical practice. We conducted a scoping review to evaluate how end points have been defined in SE research and to identify key areas of variability. Comprehensive searches of MEDLINE, Embase, and CENTRAL (Cochrane Central Registry of Controlled Trials; 1980–2025) yielded 3940 citations (1674 unique). After screening, 207 studies met the inclusion criteria and were charted using scoping review methodology (Preferred Reporting Items of Systematic Reviews and Meta‐Analyses, extension for scoping reviews). Data were extracted on terminology, electroencephalography (EEG) use, temporal thresholds, and definitions of therapeutic success across retrospective and prospective designs. Five domains of heterogeneity were identified: (1) semantic terminology (e.g., “resolved,” “controlled,” “terminated,” “cessation”); (2) EEG confirmation of the SE end point (reported in 54% of studies, with variable criteria); (3) whether time was included in defining the end point; (4) how quickly seizures were judged to have stopped, based on clinical signs, EEG findings, or both; and (5) how long seizure freedom had to be maintained to count as a successful end point. No consistent global or time‐based patterns were identified, and overlapping terminology further limited comparison across studies. Despite established consensus definitions for SE onset, the end point remains variably defined, undermining methodological rigor and limiting cross‐study synthesis. A unified, consensus‐driven framework is urgently needed to standardize SE end points through the use of standard terminology and methodologies, thereby strengthening clinical trial design and facilitating regulatory evaluation of novel therapies.